EBS

+ Watchlist + Portfolio

Emergent BioSolutions Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $4.89
52-Week Range: $4.36 – $14.06
Market Cap: $247.14M
P/E (TTM): —
EPS (TTM): -3.41
Dividend Yield: —

Advanced Metrics

Price/Book: 0.72
PEG Ratio: 0.38
Return on Equity: -40.29%
Return on Assets: 6.93%
Gross Margin: 49.39%
Operating Margin: 28.34%
Profit Margin: -22.96%
Current Ratio: 5.42
Debt/Equity: 1.72
Total Debt: $588.20M
Free Cash Flow: $37.50M
Revenue Growth: 66.30%
Earnings Growth: —
Enterprise Value: $695.64M

EBS Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$1.08B	$1.02B	$1.01B	$705.20M
Cost of Revenue	$693.10M	$705.40M	$681.30M	$326.20M
Gross Profit	$383.00M	$317.60M	$332.30M	$379.00M
Research & Development	$188.30M	$111.40M	$70.70M	$53.20M
Selling, General & Admin	$339.50M	$368.40M	$308.00M	$186.10M
Operating Expenses	$546.30M	$519.10M	$413.80M	$266.70M
Operating Income	-$163.30M	-$201.50M	-$81.50M	$112.30M
EBITDA	-$38.40M	-$518.20M	$36.90M	$237.90M
Pretax Income	-$219.00M	-$731.20M	-$142.90M	$82.80M
Income Tax	-$7.40M	$29.30M	$47.70M	$30.20M
Net Income	-$211.60M	-$760.50M	-$190.60M	$52.60M
Diluted EPS	-4.47	-14.85	-3.60	0.93
Diluted Shares	50.10M	51.20M	53.00M	56.70M

EBS Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$642.60M	$111.70M	$99.50M	$205.40M
Receivables	$159.20M	$191.00M	$154.50M	$84.20M
Inventory	$350.70M	$328.90M	$311.70M	$343.40M
Current Assets	$1.21B	$679.50M	$598.70M	$662.50M
Total Assets	$3.17B	$1.82B	$1.39B	$1.32B
Current Liabilities	$1.23B	$651.30M	$162.40M	$132.20M
Long-Term Debt	$448.50M	$446.50M	$663.70M	$572.10M
Total Debt	$1.41B	$860.20M	$663.70M	$572.10M
Total Liabilities	$1.78B	$1.17B	$906.90M	$796.00M
Retained Earnings	$738.70M	-$21.80M	-$212.40M	-$159.80M
Shareholders' Equity	$1.39B	$649.30M	$482.80M	$522.60M
Working Capital	-$18.50M	$28.20M	$436.30M	$530.30M
Net Debt	$763.20M	$748.50M	$564.20M	$366.70M

EBS Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$34.10M	-$206.30M	$58.70M	$170.60M
Capital Expenditure	-$115.80M	-$51.60M	-$22.90M	-$13.80M
Free Cash Flow	-$149.90M	-$257.90M	$35.80M	$156.80M
Depreciation & Amortisation	$143.30M	$125.10M	$108.80M	$95.80M
Stock-Based Compensation	$45.10M	$23.10M	$18.00M	$16.20M
Investing Cash Flow	-$381.30M	$212.30M	$125.20M	$69.40M
Financing Cash Flow	$481.20M	-$535.70M	-$190.00M	-$136.60M
Share Repurchases	-$82.10M	$0.00	$0.00	-$24.90M
Net Change in Cash	$65.80M	-$529.70M	-$6.10M	$103.40M

EBS Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$209.10M	$130.30M	$222.00M	$143.80M	$149.70M
Cost of Revenue	$88.50M	$66.90M	$85.90M	$84.90M	$72.00M
Gross Profit	$120.60M	$63.40M	$136.10M	$58.90M	$77.70M
Research & Development	$15.10M	$12.50M	$13.50M	$12.10M	$10.50M
Selling, General & Admin	$52.40M	$43.70M	$38.90M	$51.10M	$46.60M
Operating Expenses	$70.70M	$61.80M	$59.60M	$74.60M	$67.20M
Operating Income	$49.90M	$1.60M	$76.50M	-$15.70M	$10.50M
EBITDA	$132.80M	$21.40M	$96.20M	-$12.50M	$47.90M
Pretax Income	$92.70M	-$16.80M	$57.60M	-$50.70M	$13.40M
Income Tax	$24.70M	-$4.80M	$6.40M	$3.90M	$6.60M
Net Income	$68.00M	-$12.00M	$51.20M	-$54.60M	$6.80M
Diluted EPS	1.19	-0.22	0.91	-1.04	0.07
Diluted Shares	57.30M	54.20M	56.50M	52.40M	56.50M

EBS Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$149.10M	$267.30M	$245.50M	$205.40M	$160.30M
Receivables	$203.70M	$79.80M	$149.50M	$84.20M	$121.60M
Inventory	$314.00M	$338.60M	$356.30M	$343.40M	$327.60M
Current Assets	$706.80M	$719.50M	$786.90M	$662.50M	$637.60M
Total Assets	$1.43B	$1.42B	$1.46B	$1.32B	$1.32B
Current Liabilities	$111.90M	$127.10M	$136.50M	$132.20M	$148.70M
Long-Term Debt	$665.70M	$667.80M	$663.10M	$572.10M	$573.60M
Total Debt	$665.70M	$667.80M	$663.10M	$572.10M	$573.60M
Total Liabilities	$873.40M	$880.90M	$878.50M	$796.00M	$797.30M
Retained Earnings	-$144.40M	-$156.40M	-$105.20M	-$159.80M	-$153.00M
Shareholders' Equity	$552.70M	$536.20M	$582.50M	$522.60M	$523.10M
Working Capital	$594.90M	$592.40M	$650.40M	$530.30M	$488.90M
Net Debt	$516.60M	$400.50M	$417.60M	$366.70M	$413.30M

EBS Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$11.20M	$106.40M	-$2.30M	$77.70M	-$33.80M
Capital Expenditure	-$3.60M	-$2.90M	-$3.40M	-$3.90M	-$2.40M
Free Cash Flow	-$14.80M	$103.50M	-$5.70M	$73.80M	-$36.20M
Depreciation & Amortisation	$25.40M	$23.50M	$23.40M	$23.50M	$23.50M
Stock-Based Compensation	$1.50M	$4.60M	$4.80M	$5.30M	$1.90M
Investing Cash Flow	$59.50M	$17.20M	-$3.40M	-$3.90M	-$2.40M
Financing Cash Flow	-$400.00K	-$6.40M	-$15.90M	-$113.90M	-$11.40M
Share Repurchases	$0.00	-$6.90M	-$8.90M	-$9.10M	-$9.00M
Net Change in Cash	$47.90M	$117.20M	-$21.60M	-$40.10M	-$47.60M

Market Snapshot

About

Emergent BioSolutions Inc. is a global life sciences company focused on providing medical countermeasures and life-saving vaccines against chemical, biological, radiological, nuclear, and emerging infectious disease threats. The company develops, manufactures, and delivers products including anthrax vaccines, smallpox treatments, and therapeutics for botulism and other bioterror agents. Emergent gained prominence during the COVID-19 pandemic through vaccine manufacturing partnerships. The company serves both government and commercial markets worldwide.